Clinical Scorecard: Advocating for Safe Therapeutic and Gastrointestinal Approaches for Obese Adolescents and Young Adults with Leukemia Requiring Transplantation

At a Glance

Key Highlights

• Obesity correlates with higher rates of non-relapse mortality and poorer survival in AYA leukemia patients, with specific statistics to be included.
• Obese AYA patients experience increased toxicity and complications during leukemia treatment, supported by relevant studies.
• Use of ideal body weight for chemotherapy dosing is recommended to mitigate risks associated with obesity, with examples of dosing adjustments.

Guideline-Based Recommendations

Diagnosis

Management

• Normalize dosing of conditioning chemotherapy to ideal body weight for overweight or obese patients.
• Consider additional supportive care measures tailored to the unique needs of obese AYA patients.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Adolescents and Young Adults with leukemia and obesity

Obesity negatively impacts treatment outcomes and may require adjusted chemotherapy dosing strategies.

Clinical Best Practices

• Implement aggressive monitoring for complications in obese AYA patients undergoing HSCT, including specific metrics to track.
• Consider pharmacological and surgical management of obesity prior to HSCT, detailing potential interventions.

Related Resources & Content

• Doney et al. (2019)
• Ghasoub et al. (2025)